Evidence map›Paper›PMID 27693426›Full record

ArticleStem cell reports2016

Restoration of Corneal Transparency by Mesenchymal Stem Cells.

Sharad K Mittal, Masahiro Omoto, Afsaneh Amouzegar, Anuradha Sahu, Alexandra Rezazadeh, Kishore R Katikireddy, Dhvanit I Shah, Srikant K Sahu, Sunil K Chauhan

3 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04626583 phase1completednot on this mapstarted 2021, after this paper: background citation

Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells for Promoting Corneal Repair

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2021 to 2023Enrolled8ConditionsMesenchymal Stromal Cells, Cornea, Safety, Corneal DefectArmsAllogeneic MSC
NCT05204329 early_phase1completednot on this mapstarted 2024, after this paper: background citation

Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2024 to 2024Enrolled9ConditionsMesenchymal Stromal Cells, Cornea, Corneal Defect, Corneal Epithelium DefectArmsMSC Secretome Eye Drops
NCT05705024 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

Efficacy of Locally Delivered Allogeneic Mesenchymal Stem Cells for Promoting Corneal Repair

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2023 to 2026Enrolled38ConditionsCorneal UlcerArmsMesenchymal Stromal Cells, Control Solution
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Cell and Gene Therapy in Equine Ocular Disease.Veterinary ophthalmology · 2026
    Review
  5. Article
  6. Corneal Myofibroblasts Suppress T-Cell Immunity in Corneal Transplantation.Investigative ophthalmology & visual science · 2025
    Article
  7. Review
  8. Article
  9. Macrophages Transdifferentiate Into Myofibroblasts During Ocular Surface Inflammation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  10. Review
  11. Corneal strain influences keratocyte proliferation and migration through upregulation of ALDH3A1 expression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sharad K MittalSchepens Eye Research Institute, Massachusetts Eye and Ear, 20 Staniford Street, Boston, MA 02114, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
Masahiro OmotoSchepens Eye Research Institute, Massachusetts Eye and Ear, 20 Staniford Street, Boston, MA 02114, USA; Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Afsaneh AmouzegarSchepens Eye Research Institute, Massachusetts Eye and Ear, 20 Staniford Street, Boston, MA 02114, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
Anuradha SahuSchepens Eye Research Institute, Massachusetts Eye and Ear, 20 Staniford Street, Boston, MA 02114, USA.
Alexandra RezazadehSchepens Eye Research Institute, Massachusetts Eye and Ear, 20 Staniford Street, Boston, MA 02114, USA.
Kishore R KatikireddySchepens Eye Research Institute, Massachusetts Eye and Ear, 20 Staniford Street, Boston, MA 02114, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
Dhvanit I ShahBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02114, USA.
Srikant K SahuSchepens Eye Research Institute, Massachusetts Eye and Ear, 20 Staniford Street, Boston, MA 02114, USA; L.V. Prasad Eye Institute, Bhubaneswar, Odisha 751024, India.
Sunil K ChauhanSchepens Eye Research Institute, Massachusetts Eye and Ear, 20 Staniford Street, Boston, MA 02114, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA. Electronic address: sunil_chauhan@meei.harvard.edu.

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Ocular Immune Regulation by Mesenchymal Stem CellsR01EY024602 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI CHAUHAN, SUNIL K · 2015 to 2025
$6.5M
Biomechanical Stimulation of Hemogenic Endothelial Cells to Develop Clinical-Grade Hematopoietic Stem CellsR01HL131645 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI SHAH, DHVANIT INDRAVADAN · 2016 to 2019
$1.6M
Analysis of Mammalian Hematological Diseases in a Mouse Atpif1 Deficient ModelsR03DK100672 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAH, DHVANIT INDRAVADAN · 2014 to 2015
$177k
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY024602NHLBI NIH HHS R01 HL131645NIDDK NIH HHS R03 DK100672
6 · The paper itself

Abstract

Transparency of the cornea is indispensable for optimal vision. Ocular trauma is a leading cause of corneal opacity, leading to 25 million cases of blindness annually. Recently, mesenchymal stem cells (MSCs) have gained prominence due to their inflammation-suppressing and tissue repair functions. Here, we investigate the potential of MSCs to restore corneal transparency following ocular injury. Using an in vivo mouse model of ocular injury, we report that MSCs have the capacity to restore corneal transparency by secreting high levels of hepatocyte growth factor (HGF). Interestingly, our data also show that HGF alone can restore corneal transparency, an observation that has translational implications for the development of HGF-based therapy.

Indexed as

RegenerationAnimalsCell LineCorneaCorneal InjuriesFibroblastsGene ExpressionHepatocyte Growth FactorHumansInterleukin-1betaMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceModels, AnimalRNA, Small InterferingWound HealingHepatocyte Growth FactorInterleukin-1betaRNA, Small Interfering

Identifiers

PMID27693426
PMCPMC5063582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.